Cisbio International Opens New Facility in Massachusetts
Cisbio International last week announced it has established a new custom labeling facility in Bedford, Mass.
The new 3,500-square-foot site, which will officially open this month, will provide labeling and assay development services for the company’s US pharmaceutical and biotechnology customers, and is the first US location for the Bagnols, France-based company.
Last month Cisbio announced collaborations with three assay instrumentation makers, all of which have validated Cisbio’s patented HTRF-based assays on their platforms. (see Inside Bioassays, 8/17/2004)
Discovery Partners Awarded NIH Roadmap Contract
Discovery Partners International said that it has been awarded a multi-year contract by the National Institutes of Health to establish and maintain a small molecule repository for up to one million chemical compounds that will be provided to NIH screening centers under the NIH Roadmap.
The compounds stored in the repository are to come from a variety of sources, including commercial and academic ones, and will be used to screen known and novel targets by a consortium of chemical genomics screening centers.
According to DPI, the estimated funding of its contract for the base period between August 2004 and December 2008 is roughly $24 million. The repository will be housed with the company’s chemistry division in San Francisco.
Additional terms of the contract were not disclosed.
Thermo Electron to Provide Lab Automation Tech to Novartis Institutes
Thermo Electron announced that it has signed an agreement with the Novartis Institutes for Biomedical Research, in which Thermo will supply ultra high-throughput screening automation technology to the Novartis Institutes’ new global research headquarters in Cambridge, Mass.
The Novartis Institutes will be using Thermo’s CRS Dimension4 Distributed Motion System for high-throughput screening. The Dimension4 is a modular laboratory automation platform for virtually any laboratory assay, method, or protocol, Thermo said.